Cassandra Pardini, PharmD

Contributing Writer https://www.empr.com

Cassandra Pardini is a freelance writer and registered pharmacist with a diverse background in drug therapy, scientific research, and the drug discovery and developmental process. She obtained her Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences University, Master of Science degree in chemistry and chemical biology from Northeastern University, and Bachelor of Science degree in chemistry from Boston College. She currently lives in Rhode Island with her husband and 3 children.

All articles by Cassandra Pardini, PharmD

Maternal Tdap vaccination lowers risk of pertussis in newborns

News

COVID-19 Vaccines vs Other Vaccines: Myopericarditis Risk Compared

Cassandra Pardini, PharmD

April 12, 2022

The authors searched 4 international databases for studies reporting on myopericarditis in temporal relation to vaccination in the general population.

Doctor talking to patient while taking notes.

News

Survey Suggests COVID-19 Vaccine Approval Had Little Impact on Unvaccinated

Cassandra Pardini, PharmD

April 11, 2022

At the beginning of 2022, 25% of American adults were found to remain partially vaccinated or unvaccinated against COVID-19.

News

Patient Education Important With Antiseizure Med Generic Substitutions

Cassandra Pardini, PharmD

March 24, 2022

Pharmacotherapeutic issues associated with generic substitutions of antiseizure medications may not only be the result of the FDA’s bioequivalence standards.

News

Management of Drug-Induced Diabetes Discussed in Review

Cassandra Pardini, PharmD

March 10, 2022

The study authors focused on 4 pharmacologic classes: glucocorticoids, antiretroviral therapies, newer atypical antipsychotics, and immune checkpoint inhibitors.

ASCO GU 2022

Bladder-Sparing Therapies for Localized Muscle-Invasive Bladder Cancer Compared

Cassandra Pardini, PharmD

February 18, 2022

The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.

ASCO GU 2022

Immune Checkpoint Inhibitor Combo Therapy Assessed in mRCC Patients With Poor Performance Status

Cassandra Pardini, PharmD

February 18, 2022

Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.

ASCO GU 2022

Long-Term Data Support Avelumab as First-Line Maintenance in Advanced Urothelial Carcinoma

Cassandra Pardini, PharmD

February 17, 2022

Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.

ASCO GU 2022

Study Identifies Treatment Preferences in Advanced Renal Cell Carcinoma

Cassandra Pardini, PharmD

February 17, 2022

The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.

ASCO GU 2022

Pharmacotherapies for First-Line Treatment of mCSPC Explored

Cassandra Pardini, PharmD

February 17, 2022

The network meta-analysis aimed to compare various combinations of treatment options to determine the safest and most effective management strategy for mCSPC.

ASCO GU 2022

Serologic Outcomes Following COVID-19 Vaccination Assessed in Patients With Genitourinary Cancer

Cassandra Pardini, PharmD

February 17, 2022

The study included a total of 183 patients with genitourinary cancers.